Nearly 30% of traditional pharmaceutical companies have shrunk, and R&D talents lead the salary ranking. The salary of the pharmaceutical industry in 2021 will be released. Are you averaged?

30% of clinical operation talents expect a 38% salary increase in 2022; 30% of drug registration talents expect a 22% salary increase;

More than 24% of multinational pharmaceutical companies and more than 26% of large local pharmaceutical companies will experience a certain degree of scale reduction in 2021;

70% of people working in early stage R&D believe that their company will expand significantly in 2022;

Under the background that the national volume procurement and medical insurance negotiation are becoming normalized and institutionalized, the national drug review and approval reform is becoming more and more perfect, and the industrial innovation and transformation is accelerating, and in the current changing pattern of increasingly fierce competition in the pharmaceutical industry, talent has become a pharmaceutical company.
one of its core competencies
.

Simply put, changes in employee salaries reflect the needs of enterprises and industries for talents
.

From VP-level executives to general medical representatives, salary is a microcosm of the development of an enterprise and even an industry, and the trend of salary changes also indicates the prospects for the development and changes of the industry

A few days ago, Aohuo Consulting released the "2022 Greater China Pharmaceutical Industry Salary Report" (hereinafter referred to as "Report"), through the survey results of thousands of medical practitioners and the active job data of Aohuo talent pool in 2021 The summary analysis shows us the current talent demand and salary level of the pharmaceutical industry, and provides insight into the future talent needs of the pharmaceutical industry segments
.

What are the differences in talent demand among multinational pharmaceutical companies, domestic traditional pharmaceutical companies, and domestic innovative pharmaceutical companies? Which functional departments are the most "popular" in pharmaceutical companies? Who is at risk of being laid off? What are the salary levels for different positions?

01.
Layoffs or expansion?

01.
Layoffs or expansion?

The change of the enterprise scale reflects the influence of the pharmaceutical market on the enterprise and the adjustment of the enterprise's own development strategy
.

The "Report" shows that in the past year, more than 24% of multinational pharmaceutical companies have experienced a certain reduction in scale, and this reduction is also reflected in 26% of large local pharmaceutical companies
.

Li Yan, founder of Aohuo Consulting, said that "the scale of personnel must be reduced" has two meanings

Changes in the scale of personnel in different types of pharmaceutical companies (Source: Aohuo Consulting's "2022 Greater China Pharmaceutical Industry Salary Report")

With the continuous advancement and improvement of national pharmaceutical policies such as centralized procurement and medical insurance negotiation, multinational pharmaceutical companies have adjusted their businesses to adapt to the new domestic pharmaceutical environment
.

For example, Roche China and Pfizer China both started business model optimization or organizational structure adjustment last year

This adjustment and transformation is not only the optimization of the structure, but also accompanied by changes in personnel and scale such as resignation and layoffs
.

After the sixth batch of special insulin collection in November last year, there were rumors in the industry that "the leading insulin company Novo Nordisk will lay off 15% to 20% of its employees nationwide"; President of Eli Lilly China Ji Liwen said that Lilly's PD-1 product line has about 300 people nationwide, and these employees will all be transferred internally or laid off; Daiichi Sankyo plans to merge cardiovascular, anti-infection and respiratory analgesia lines, and lay off related teams; Ogallon has carried out layoffs for CV in some regions; Sanofi has adjusted staff in some business lines, etc.

AstraZeneca may have the most frequent and largest changes in structure and personnel in MNC: Digestive and respiratory nebulization business merged to establish Digestive and respiratory nebulization business department; Cardiovascular and Metabolism business department and kidney business department merged to establish cardiovascular and nebulization business department.
, Kidney and Metabolism Business Department; Hexian Business was split, Hexian Oncology Business was merged into Oncology Business Department, and County Non-Oncology Business was established as Hexian Chronic Disease Business Department; Rare Disease Business Department and Omni-Channel Business Department were also established .
.
.
It's not just that 7 executives "run away" one after another, "AstraZeneca may have laid off more than 2,000 people in the process of restructuring
.

" Li Yan revealed

Not only multinational pharmaceutical companies, but under the influence of today's changing pharmaceutical industry environment, the life of the old Chinese traditional pharmaceutical companies is also difficult
.

In mid-2021, Hengrui announced changes in several product lines, and product sales in some provinces and regions will be handed over to the Imaging Division; Yiling Pharmaceutical and Harbin Pharmaceutical Group also made large-scale layoffs due to performance losses

For traditional big pharmaceutical companies, their own performance is affected by many factors such as market and policies
.

For example, towards normalized centralized procurement, the exchange of price for quantity is becoming more and more intense, and the profit space of enterprises is constantly being squeezed.

The most significant change in the scale of personnel is that national centralized procurement has become one of the main reasons for corporate layoffs
.

"When a product is included in volume procurement, whether it is selected or unsuccessful, the demand for medicine will drop sharply, and the abolition of the sales team is a routine action today

Contrary to the reduction of nearly 30% of the scale of multinational pharmaceutical companies and traditional pharmaceutical companies, the innovative upstarts are showing a trend of expansion.
72% of the innovative upstarts will achieve a substantial increase in the size of their personnel in 2021.
4 times that of pharmaceutical companies, showing the strong potential of innovative upstarts
.
"On the one hand, the substantial expansion is due to the relatively sufficient funds.
With the advancement of clinical research projects, the stamina is strong, and the demand for talents continues to increase
.
" Li Yan said that with the blessing of capital, innovative pharmaceutical companies are confident in the competition for talents.
For a long time, this expansion of talent demand will continue to increase
.
For the expanding innovative pharmaceutical companies, after successfully introducing talents, how to retain and develop talents will be the focus in the future
.

Under the current changing background of the pharmaceutical market, whether it is a local traditional pharmaceutical company, an innovative upstart or a multinational pharmaceutical company, it is necessary to continuously adjust the talent and product structure according to the market development trend and their own needs to adapt to the new industry needs
.

02.
R&D and BD talents take the lead in salary

02.
R&D and BD talents take the lead in salary

The report also observes and forecasts the market demand for talents in key areas in the whole process of the pharmaceutical industry, such as early drug research and development, clinical development, medical affairs, and business marketing
.

Early-stage R&D talent is optimistic about 2022
.
Under the policy guidance and the needs of the capital market, the importance of early R&D teams to pharmaceutical companies has become more and more prominent, and the market demand has also become hot
.
Aohuo Consulting survey shows that more than 70% of talents engaged in early R&D work believe that their company will have a large-scale expansion in 2022, and nearly 40% of the respondents have a 40% salary for their next job.
increase expectations
.
"The imbalance between supply and demand may further increase the possibility of competition
.
" Aohuo Consulting said that currently hot jobs in this field are still crowded together, especially in the field of tumor and immunity, nucleic acid, ADC, and gene therapy are all popular directions
.

In terms of clinical operation and drug registration, with the introduction of a series of policies such as the Reform of the Review and Approval System for Drugs and Medical Devices and the Consistency Evaluation of the Quality and Efficacy of Generic Drugs, in 2021, data from the CDE drug clinical trial registration platform shows that A total of 3,247 clinical trials were announced, a year-on-year increase of 2.
7%
.
Among them, international multi-center trials accounted for 309, a year-on-year increase of 51.
5%
.
The ever-increasing number of clinical trials has increased the demand of pharmaceutical companies for clinical operation talents, and especially focuses on whether the talents have NDA and BLA application experience
.

For talents in the field of clinical operation and drug registration, companies not only value whether the talents have a global vision and whether they participate in international multi-center clinical trials, but also put forward higher requirements for talents' transnational and cross-departmental cooperation and communication
.
However, in terms of salary increases, pharmaceutical companies tend to gradually calm down and rationally evaluate the cost performance of talents
.
The talent levels required by different types of companies are also different.
For multinational pharmaceutical companies and mature innovative drug companies, the talent needs are concentrated in manager or senior manager-level positions
.
For start-up pharmaceutical companies, talent needs are concentrated at the level of registered director or person in charge
.

Judging from the salary survey data, talents in clinical operations and drug registration have shown high expectations for salary increases
.
"This is completely in line with the current situation in which clinical operations and drug registration talents are in short supply
.
" Aohuo Consulting said
.
Data shows that more than 30% of clinical operation talents expect a salary increase of 38%; 30% of drug registration talents expect a salary increase of 22%
.
"The popularity of clinical operations and drug registration talents in the market undoubtedly poses new challenges for companies to recruit
.
"

With the vigorous development of innovative drug research and development in China, especially in the fields of oncology, immunity and rare diseases, pharmaceutical companies have accelerated the launch of new drugs through independent research and development and product authorization
.
Driven by this situation, clinical development and medical affairs talents have become particularly important
.
Generally speaking, the salary competitiveness of multinational companies and innovative pharmaceutical companies is better at present, and at the same time, multinational companies have higher requirements on the background and qualifications of job candidates
.
In most innovative drug companies and a small number of multinational pharmaceutical companies, in addition to the fixed income in cash, high-level candidates will also have non-cash income such as options or stocks, and the higher the level, the non-cash part of the salary The proportion of the total will also be higher
.
Aohuo Consulting predicts that this field will still be in short supply in 2022, and most talents will expect a salary increase of 20%-30%, especially in the fields related to tumor and immunity, the salary level of talents will be higher
.

Product licensing transactions are one of the main ways for pharmaceutical companies to cooperate.
Today, with the rapid development of China's biopharmaceutical industry and the ever-evolving ecology, the pattern of competition and cooperation between pharmaceutical companies is becoming more and more complex, which also poses new challenges to BD's capability requirements
.
In 2021, the trend of domestic pharmaceutical companies going overseas is more obvious.
Therefore, in the demand for BD talent recruitment, a large number of recruitment positions for license-out BD talents have also been added
.
At the same time, with the increase in the number of license-in projects of pharmaceutical companies, companies pay more attention to the roles of R&D portfolio strategy and project management, and the demand is on the rise
.

Drug safety issues accompany the entire life cycle of drugs.
In 2021, the State Food and Drug Administration promulgated the "Pharmacovigilance Quality Management Standard" which clearly stipulates the staffing, system establishment, work scope and requirements of enterprise pharmacovigilance.
The challenges brought by work have spawned a large number of pharmacovigilance jobs, especially mature pharmacovigilance practitioners are hot spots for market competition
.
A person in charge of pharmacovigilance of a pharmaceutical company once said, "Pharmaceutical companies need to build a pharmacovigilance team, but now there are not many people with rich experience in the industry, and even fewer people with global experience.
Said, next will face the situation of 'headhunting and poaching'
.
"

In addition, under the influence of policies, the pressure on pharmaceutical companies to access medical insurance has also increased
.
From the previous hospital-level market access, to regional bidding, to the national medical insurance negotiation, pharmaceutical companies will further increase the demand for access and key account management talents to adapt to the market changes brought about by future policy orientations
.

The demand for different types of talents is also directly reflected in the salary.
Comparing VP positions, the highest salaries are in the R&D and BD fields, the vice president of medicine and the chief business development officer in the pre-market clinical medicine sector, and the median salary in the first-tier cities is average.
2.
5 million yuan; the vice president of biology in the pharmaceutical R&D section, the vice president of pharmacy in the pharmaceutical R&D section, the vice president of statistics/data statistics in the data statistics section, the median salary in the first-tier cities is 2 million yuan; the process production section The vice president of process development, CMC The median salary of vice presidents in first-tier cities is 1.
8 million yuan
.

Source: Aohuo Consulting "2022 Greater China Pharmaceutical Industry Salary Report"